# Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)

> **NCT00745511** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ora Bio Ltd.** · enrollment: 96 (estimated)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** ORA102 and Avastin
- **DRUG:** Avastin

## Key facts

- **NCT ID:** NCT00745511
- **Lead sponsor:** Ora Bio Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-03
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2009-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00745511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00745511, "Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00745511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*